Drug development for rare diseases is often led by patients and their families. The rare disease community spends countless hours and dollars searching for and funding treatments to mitigate the effects of their rare disease. All too often, a lack of expertise can result in years of wasted money and time.
Through Brydge Solutions partnerships, Odylia reduces inefficiencies commonly found on the path from early discovery to clinical trials. With years of expertise in rare disease research, drug development, and program management, Odylia empowers Brydge Solutions program partners and provides the resources to help groups maintain momentum and control over their interests.
We leverage our internal scientific and drug development expertise to provide the following services at a subsidized rate to patient groups, while we also partner with industry and VC groups:
Frustrated by timelines or timely access to scientific expertise? Odylia recognizes the growing need for Patient Groups to expand their bandwidth and capacity. Through the Concierge Service we can build a team to address your organization’s needs by leveraging our internal scientific and operational expertise . We have helped Patient Groups accelerate drug development timelines, mitigate risks, make critical research tools available to their research communities, build their networks, and optimize investments in research. Through timely and consistent touch-points and rapid execution we can advise and directly manage your portfolio. Lean on your Odylia Concierge Team to enhance organizational structure and enhance communication and increase efficiencies in the research communities you are investing. We can help you build momentum for your drug development programs.
By saving time, money, and, most importantly, improving the success rate of therapeutic development, we strive to make drug development work for patients, not for profits. Odylia tailors solutions to meet each group’s needs. These partnerships range in scope from deliverable-based landscape analyses to long-term, ongoing scientific guidance and portfolio management. We partner with patient groups or families and rare disease companies at all stages in their drug development journey.
"Having a child with a rare disease means needing to become an expert in drug development. But there are so many roadblocks and things to learn. Our partnership with Odylia's Brydge Solutions helped us better understand the science of CLOVES Syndrome and gave us a fresh perspective on therapeutic options and potential collaborators for the future."
"Odylia, through Brydge Solutions, really helped the SATB2 Gene Foundation focus and start moving in the direction we need to be moving in. Their landscape analysis broke everything down into workable goals in language that could be shared with our communities."
"Our goal is to accelerate progress as quickly as possible so we sought a partner who had the depth of expertise to provide guidance on scientific strategy, but who could also give us insights into the financial and operational aspects of our company’s growth. But what really stood out about Odylia was their accessibility and personal touch. They are as committed as we are to rare disease patients and that’s a quality that we highly value and is critical to our success."